The Grifols family won’t support a new bid by a third-party to take its namesake drug-maker private amid indications that Brookfield Asset Management may scrap plans to acquire the company.
The family “will not back another take private transaction,” a spokesperson for the Grifols family said by phone. “We are very pleased with all the letters we’ve received from existing shareholders telling us the company is worth more and we will continue working so that the company’s value increases even more.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.